As Merck KGaA launches a global rebrand that will mean Merck Serono and Merck Millipore are known simply as Merck in all markets outside Canada and the US, the company has named deputy chief executive Stefan Oschmann as the new CEO. He will take the position after Karl-Ludwig Kley retires next year. The company has also announced that Laszlo Radvanyi will be its new senior vice president, head of research in immuno-oncology. Laszlo brings extensive immuno-oncology expertise to the role, having spent 10 years conducting research on tumour infiltrating lymphocytes and more than 25 years studying cellular and molecular immunology. Prior to joining Merck, he served as chief scientific officer at Lion Biotechnologies.
Roche has appointed Richard Erwin as its new general manager in the UK. Richard joins Roche in the UK from his role as general manager in Belgium/Luxembourg, following 27 years at the company. He worked initially in UK sales, marketing and clinical operations roles before moving into European and global leadership.
Diabetes clinical and research specialist Professor Stephen Gough has joined Novo Nordisk as senior principal clinical scientist. In his new role in Denmark, Stephen will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to Phase III and beyond for the treatment of diabetes and obesity. He joins the company from the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) and will remain as a visiting professor of diabetes and fellow of Harris Manchester College, Oxford University.
Peter Lidstone has been appointed as director of blood manufacturing and logistics at NHS Blood and Transplant. Peter has extensive experience in manufacturing and logistics in the fine chemicals, food and coatings industries. He has led transformational projects and continuous improvement programmes to drive safety, service, quality, costs and engagement towards world class levels. He will lead blood and blood component manufacturing in five centres across England and operate a 24/7 logistics fleet delivering routine and emergency blood products to hospitals.
Former DDB Remedy chairman and creative director Orrin Pollard has joined behaviour change agency Hamell as partner and executive creative director to launch their new communications division, Hamell Ignyte. Together with managing director Fiona Hammond and clinical director Alison Carr, Orrin will be helping to improve communication between pharma clients, healthcare professionals, patients and consumers. "I am looking forward to being a part of a truly differentiated offer. Many agencies talk about changing behaviour, but few actually have the evidence to back it up,” says Orrin.
Stephen Dorrell has been named as the new chair of the NHS Confederation. The former secretary of state for health and the first elected chair of the Health Select Committee, Stephen has a parliamentary career spanning 36 years. He will work with the board of trustees to ensure the NHS Confederation continues to be a system leader and a representative voice of its members, while giving direct support for NHS leaders delivering the best possible care to patients.
The BIA has announced that Dr Jane Osbourn, vice president of research and development at MedImmune, will be the new chair of its board from January 2016. The announcement was made at the BIA annual general meeting in October, where four new board members were elected: Dr Darrin Disley, CEO of Horizon Discovery Group; David Hipkiss, chief business officer of Circassia Pharmaceuticals; Dr Andrew Lightfoot, CEO of Peptinnovate; Dr Neil Murray, CEO of Redx Pharma. Also, Dr Celia Caulcott, vice-provost (Enterprise) at UCL Business was re-elected.
MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating (DUB) enzymes to treat cancer and other diseases, has appointed David Luther as chief financial officer. David brings more than 25 years’ financial and operational experience across the healthcare, FMCG and pharmaceutical industries. He joins MISSION from Spotless Group, a private equity backed FMCG business, where he was VP Finance for commercial and supply chain operations in the UK, Ireland and Italy.
Vedanta Biosciences, a PureTech Health company focused on the development of therapies to modulate the human microbiome, has appointed Lisa Rae Schopf as head of preclinical development and Erik Spek as head of intellectual property. Lisa previously served as senior director of preclinical development at clinical-stage pharma company Kala Pharmaceuticals, while Erik joins from biopharmaceutical company Epizyme, where he served as director of IP.
The Academic Health Science Network for the North East and North Cumbria (AHSN NENC) has named Carol Nicholson as deputy director of innovation and wealth creation. Carol brings with her over 30 years' experience in NHS settings across the UK, the last 12 in commissioning roles at primary care trusts and clinical commissioning groups in the North East, largely focusing on planning, performance and provider management. Carol will be helping NHS organisations and SMEs to navigate this complex landscape through the implementation of the AHSN’s Innovation Pathway initiative, with an initial focus on ensuring CCGs receive maximum benefit.from AHSN support.
Dr Neil Brewis has joined immuno-oncology biopharma F-star as chief scientific officer. Neil previously worked at GlaxoSmithKline (GSK) as vice president, head of biopharmaceutical research, where he led a global team of 300 scientists who advanced numerous monoclonal antibodies, antibody fragments, and protein therapeutics from target validation into early clinical development. This involved leading teams focused on pipeline discovery, platform innovation, translational medicine, clinical immunology, manufacturing process research and cell line development.
Hubertus von Baumbach will succeed Professor Andreas Barner as chairman of the board of managing directors at Boehringer Ingelheim. Hubertus has been a member of the board of managing directors since 2009 and is head of the Corporate Board Division Finance. Following periods at Roche in the USA and at BI in Canada, he performed various functions in the finance division at Boehringer Ingelheim in Germany. Dr Michel Pairet will also become a member of the board with responsibility for the Corporate Business Division Research and Nonclinical Development.
Global healthcare communications consultancy 90TEN has recruited Paula Hensler to head its editorial team. A hospital doctor by training, Paula has previously held a number of high-profile editorial and event directorship positions including clinical editor of GP magazine, editor of MIMS Oncology & Palliative Care and director of medical conferences at Haymarket Medical. Kate Haynes has also joined the team as senior medical writer from Chameleon Communications International.
Hayley Jayawardene has joined Liberation Unlimited as senior account director following a period of freelancing in-house at Pfizer and at medical education agency Real Science Communications. Prior to that, Hayley spent five years at Porter Novelli leading the UK Boehringer Ingelheim respiratory account. At Liberation Unlimited, she will work on several high-profile medical education and PR programmes focusing on respiratory, ophthalmology and corporate communications.
Zinta Krumins, managing director of Boehringer Ingelheim UK, has left to pursue other interests outside the organisation. Following Zinta’s departure, the current role of head of prescription medicine and country managing director (CMD) will be split. Klaus Dugi will continue as medical director and take on the role of chairing the executive committee as the country managing director. Michael Horn will continue as marketing director and take on the role of head of the prescription medicine business.
Global healthcare communications agency dna has recruited Heather Grant to spearhead a specialist PR unit. The new division broadens dna’s services to include scientific product, disease area, internal and corporate communications; reputation and issues management; stakeholder and advocacy group relations; and market access across the range of channels. Prior to dna, Heather spent more than six years with Chandler Chicco Companies (part of inVentiv Health), where she was part of the senior team that drove the growth and success of Biosector 2 in London.
Angela DeMarchi has joined healthcare marketing consultancy Uptake Strategies as marketing consultant from her role as senior brand manager at Boehringer Ingelheim. Angela brings a wealth of experience in pharmaceutical marketing, launch and brand planning and will be working with a range of healthcare clients.
Quintiles has announced that Kevin Gordon, currently serving as executive vice president of operations and CFO, has been promoted to chief operating officer and that Michael McDonnell is expected to join the company in December as executive vice president, CFO. Under Kevin’s financial leadership, Quintiles has delivered an eight percent compound annual growth rate in net revenue and 14 percent growth in Adjusted EBITDA since 2010. Michael joins Quintiles from Intelsat, where he has served as CFO since 2008.
The Sync Project, a global collaboration harnessing the scientific potential of music for health, has appointed Yadid Ayzenberg as chief technology and product officer and Dame Marjorie Scardino to its board of directors. Dame Marjorie served as chief executive of The Economist for 12 years and then Pearson plc, the world's leading education company, for 16 years. She is currently chairman of the MacArthur Foundation, one of the largest private foundations in the United States. Yadid is a researcher in the Affective Computing Group at the MIT Media Lab, working on the application of new technologies to solve healthcare problems, and will be responsible for leading the development of the Sync Project platform.